297149-32-7

Basic information

• Product Name: 1H-Pyrazole-3-carboxamide,5-nitro-(9CI)
• Synonyms: 1H-Pyrazole-3-carboxamide,5-nitro-(9CI);5-nitro-2H-pyrazole-3-carboxamide
• CAS NO: 297149-32-7
• Molecular Formula: C4H4N4O3
• Molecular Weight: 156.09956
• Product Categories: AMIDE
• Mol File: 297149-32-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazole-3-carboxamide,5-nitro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxamide,5-nitro-(9CI)(297149-32-7)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxamide,5-nitro-(9CI)(297149-32-7)

Safety Data

• Hazardous Substances Data: 297149-32-7(Hazardous Substances Data)

Usage

Structure

A pyrazole ring with a carboxamide group and a 5-nitro substituent

Type

Nitro derivative of pyrazole-3-carboxamide

Main uses

Pharmaceutical and research applications

Unique properties

The 5-nitro substituent on the pyrazole ring gives 1H-Pyrazole-3-carboxamide, 5-nitro-(9CI) unique properties and potential biological activities.

Biological activities

Potential antibacterial, antifungal, and antiparasitic properties, as well as potential for use in drug development.

Synthesis

May be used as a building block in the synthesis of various organic compounds.

Interest

Due to its potential biological activities, the compound is of interest for further research and development in the pharmaceutical industry.

Upstream product

• 7664-41-7 ammonia 
• 181585-93-3 5-nitro-2H-pyrazole-3-carboxylic acid methyl ester 
• 198348-89-9 5-nitropyrazole-3-carboxylic acid 

Downstream Products

• 1204246-72-9 3-nitro-1H-pyrazol-5-carbonitrile 

Relevant articles and documents

Novel quinazoline-containing compound, and intermediate and application thereof

The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.

4-((1H-pyrazol-3-yl)amino)phthalazin-1(2H)-one derivatives and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient

The present invention relates to a 4-((1H-pyrazol-3-yl)amino)phthalazine-1(2H)-one derivative and a pharmaceutical composition for preventing or treating cancer containing the same as an active component. The derivative exhibits high inhibitory activity on various protein kinases, and in particular, has excellent inhibitory ability on RET proto-oncogene enzymes, and also has an excellent inhibitory effect on proliferation of medullary thyroid cancer cells and lung cancer cells expressing RET fusion genes, thereby being able to be usefully used for treating medullary thyroid cancer or lung cancer, and in particular, being able to be usefully used for treating cancer in which RET fusion genes are expressed.

ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.

Nitropyrazoles : 118. Synthesis and transformations of 5-amino-3,4- dinitropyrazole

A method of preparation of 5-amino-3,4-dinitropyrazole (1) from 3(5)-methyl-5(3)-nitro- and 3(5)-methyl-4,5(3)-dinitropyrazoles was developed, the key step of which was the Hofmann rearrengement of nitro- and dinitropyrazolecarboxamides. The protonation o

JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. (I).